Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Avenues in Neuromodulation

Executive Summary

Implantable neurostimulation devices have the potential to ameliorate a number of debilitating conditions in which neural pathways play a role. Combined, these applications are expected to bring in device revenues of nearly $1.4 billion in the US alone in 2010, and that number is forecast to increase by double-digits going forward, reaching over $2.6 billion by 2014, according to Medtech Insight's recently published report, "US Markets for Neurostimulation Products."
Advertisement

Related Content

Market & Industry Briefs
ASMBS Highlights New Developments in Bariatric Surgery
Neuro Panel Narrowly OKs Medtronic's Deep Brain Stim Device For Epilepsy
Apnex Medical Inc.
Device Investors Look for Gains in Pain
ImThera Medical Inc.
Medtronic's DBS Epilepsy Therapy Reduces Seizures 68% At Three Years
Medtronic's DBS Epilepsy Therapy Reduces Seizures 68% At Three Years
ACC 09 Highlights: Mostly Good News for Device Manufacturers
Start-Up News

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT035367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel